ABSTRACT
Background Adverse pregnancy outcomes (APOs) affect a large proportion of pregnancies and represent an important cause of morbidity and mortality worldwide. Yet, the pathophysiology of APOs is poorly understood, limiting our ability to prevent and treat these conditions.
Objective To search for genetic risk markers for four APOs, we performed genome-wide association studies (GWAS) for preterm birth, preeclampsia, gestational diabetes, and pregnancy loss.
Study Design A total of 9,757 nulliparas from the nuMoM2b study were genotyped. We clustered participants by their genetic ancestry and focused our analyses on the three sub-cohorts with the largest sample sizes: European (EUR, n=6,082), African (AFR, n=1,425), and American (AMR, n=846). Association tests were carried out separately for each sub-cohort and brought together via meta-analysis. Four APOs were tested by GWAS: preeclampsia (n=7,909), gestational length (n=4,781), gestational diabetes (n=7,617), and pregnancy loss (n=7,809). Using the results of the genome-wide associations for each APO, SNP-based heritability of these traits was inferred using LDscore. Putative regulatory effects were inferred by transcriptome-wide association analysis.
Results Two variants were significantly associated with pregnancy loss (rs62021480: OR = 3.29, P = 7.83×10−11, and rs142795512: OR = 4.72, P = 9.64×10−9), implicating genes TRMU and RGMA in this APO. An intronic variant was significantly associated with gestational length (rs73842644: beta = -0.667, P = 4.9×10−8). Three loci were significantly associated with gestational diabetes (rs72956265: OR = 3.09, P = 2.98×10−8, rs10890563: OR = 1.88, P = 3.53×10−8, rs117689036: OR = 3.15, P = 1.46×10−8), located on or near ZBTB20, GUCY1A2, and MDGA2, respectively. Several loci previously correlated with preterm birth (in genes WNT4, EBF1, PER3, IL10, and ADCY5), gestational diabetes (in TCF7L2), and preeclampsia (in MTHFR) were found to be associated with these outcomes in our cohort as well.
Conclusion Our study identified genetic associations with gestational diabetes, pregnancy loss, and gestational length. We also confirm correlations of several previously identified variants with these APOs.
Disclosure Statement The authors declare no conflict of interest
Source of financial support Precision Health Initiative of Indiana University, National Institutes of Health award R01HD101246 to DMH and PR. Cooperative agreement funding from the National Heart, Lung, and Blood Institute and the Eunice Kennedy Shriver National Institute of Child Health and Human Development: grant U10-HL119991 to RTI International; grant U10-HL119989 to Case Western Reserve University; grants U10-HL120034 and R01LM013327 to Columbia University; grant U10-HL119990 to Indiana University; grant U10-HL120006 to the University of Pittsburgh; grant U10-HL119992 to Northwestern University; grant U10-HL120019 to the University of California, Irvine; grant U10-HL119993 to University of Pennsylvania; and grant U10-HL120018 to the University of Utah. National Center for Research Resources and the National Center for Advancing Translational Sciences, National Institutes of Health to Clinical and Translational Science Institutes at Indiana University (grant UL1TR001108) and University of California, Irvine (grant UL1TR000153).
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Precision Health Initiative of Indiana University, National Institutes of Health award R01HD101246 to DMH and PR. Cooperative agreement funding from the National Heart, Lung, and Blood Institute and the Eunice Kennedy Shriver National Institute of Child Health and Human Development: grant U10-HL119991 to RTI International; grant U10-HL119989 to Case Western Reserve University; grants U10-HL120034 and R01LM013327 to Columbia University; grant U10-HL119990 to Indiana University; grant U10-HL120006 to the University of Pittsburgh; grant U10- HL119992 to Northwestern University; grant U10- HL120019 to the University of California, Irvine; grant U10-HL119993 to University of Pennsylvania; and grant U10-HL120018 to the University of Utah. National Center for Research Resources and the National Center for Advancing Translational Sciences, National Institutes of Health to Clinical and Translational Science Institutes at Indiana University (grant UL1TR001108) and University of California, Irvine (grant UL1TR000153).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRB of Indiana University gave ethical approval for this work as protocol Study number 1008-08 on 9/28/2010
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study will be made available online after peer review, and are available upon reasonable request to the authors
